Clinical Trial

Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO)

Study acronym: CPUO
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to assess the PK/PD relationship of nemolizumab in adult participants aged 18 years or above with chronic pruritus of unknown origin (CPUO) during a 16-week treatment period.
Protocol Amendment History 4 changes
critical Enrollment closed, study ongoing 2026-07-28
notable Primary completion pushed: 2026-09 -> 2026-12 2026-07-28
notable Trial sites expanded: 21 -> 24 locations 2026-05-02
notable Trial sites expanded: 18 -> 21 locations 2026-05-01
Trial Details
NCT Number NCT07074977
Lead Sponsor Galderma R&D
Conditions Chronic Pruritus of Unknown Origin
Enrollment 50 participants
Start Date 2025-10-20
Primary Completion 2026-12 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-27